Quantitative methods playa major part in the evaluation of new therapeutic substances. Much of the pioneer work in this field dates from 1931 when the Medical Research Council of Great Britain set up its Therapeutic Trials Committee which soon established the medical statistician as a member of the team alongside the clinician and pharmacologist (1) . In the clinical assessment of a new drug it is now generally agreed that after the basic pharmacological data have been acquired from preliminary animal experiments and from pilot trials on human subjects the information should be applied to the measurement of specified reactions against different doses of the drug. It is also necessary to establish the relationship of these reactions to the outcome of the disorder, a step which entails some knowledge of the course of the condition either without treatment or with some other form of treatment. It is then possible to proceed to the organization of the therapeutic trial which, in its classical form, is designed to compare the effects of treatment in two or more groups to each of which there has been random allocation of patients .differing only in respect of the treatment administered. The criteria of response to treatment should be as unambiguous as possible and a member of the Statistical Research Unit of the M.R.C. has pointed out that " ... whenever possible objective and preferably measured assessment of the progress of patients should be used. I tis, however, probable that this will have to be supplemented by subjective assessment" (2) . Unfortunately the difficulty of standardizing subjective responses, however, has led to their virtual neglect in this field until recent years.
The controlled therapeutic trial is not, of course, necessary for the assessment of all remedies. Such trials can be dispensed with if a previously fatal condition is treated successfully -as in the case of the treatment of tuberculous meningitis by streptomycin -or when the new agent is clearly superior to its predecessors -as in the case of the treatment of scrub typhus by chloramphenicol. Further, ethical considerations may limit the possibilities of a clinical trial in some instances, especially if there is evidence to suggest that irreversible harm could be prevented by the administration of an existing treatment. Nonetheless, in so far as it has introduced the well-tried principles of prophylactic evaluation into experimental therapeutics, the modern clinical trial enforces a healthy respect for scientific method in a field where it has not always been prominent. It is important to remember at the same time that the comparative trial is essentially an epidemiological procedure and reflects the outlook of the statistician, who inevitably tends to think less as a physician and more as a metaphysician, specializing therefore in the description of the types of proof which are appropriate to various types of statement. The commonest form in which these statements are made about the therapeutic value of psychotropic drugs has led to clinical trials designed to answer questions of this order: Are patients suffering from condition X more likely to benefit from treatment A than from treatment B (which may be a placebo)? Whether such a question can be answered with confidence depends in large measure on the precision with which it is possible to define the clinical condition and to specify the criteria of benefit. On both these counts depressive states raise particular problems.
The definition and scope of the illnesses to be treated is of prime importance for the construction of representative samples. No classification of affective conditions in clinical terms can yet be more than provisional, and recent work purport-tThis is an abridged revision of the paper that was read at the Conference. *Senior Lecturer, Institute of Psychiatry; The Bethlem Royal and Maudsley Hospitals, London, England.
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ing to distinguish depressive syndromes by means of the mathematical analysis of symptom-clusters has largely confirmed the judgment of clinical experience. There is a wide variation in the estimated frequency of these illnesses based on the most reliable figures we possess, namely the large-scale national statistics of hospital admissions. In England and Wales the manic-depressive psychoses, most of them in the form of depressive states, make up the largest diagnostic group among cases admitted to mental hospitals. By contrast, in the United States and the Scandinavian countries -where hospital statistics are also carefully compiled -the manicdepressive psychoses and involutional melancholia combine to form a relatively small proportion of cases and schizophrenia is the condition diagnosed most frequently. This discrepancy cannot be explained wholly by true differences of prevalence. Idiosyncratic classification is partly responsible: the 'psychogenic psychoses' of the Scandinavian authors, for example, include a number of illnesses which would be regarded as depressive elsewhere. In addition, the traditions of diagnostic practice itself can affect the relative estimates of the two major functional psychoses; thus American psychiatrists appear to be guided more than we in Great Britain by Nolan Lewis's dictum that " ... the diagnosis of manicdepressive psychoses can be made only by the elimination of schizophrenia" (3). The various prevalence rates of depressive illness provided by responsible workers indicate the need to consider as well the degree of disability leading to inclusion in the diagnostic category. Thus Fremming's surprisingly high figures from the island of Bornholm must be interpreted in the light of his painstaking survey methods and of the finding that 40% of his cases had not been under psychiatric care (4) . Our experience in Great Britain has shown that patients suffering from the milder forms of depressive illness have tended to enter mental hospitals in increasing numbers as provision for treatment on a voluntary basis has been extended (5) and that many other cases require extra-mural services for their detection.
It is apparent that if disregarded this clinical diversity will undermine the structure of a comparative trial which depends on commensurate severity of illness in the treated and control groups. But in addition the groups must be homogeneous in respect of outcome if comparison is to be valid. Here the tendency of depressive illnesses to run a self-limiting and often recurrent course renders prognosis difficult in even the better-defined syndromes. It is also necessary to take cognizance of the appreciable mortality rate which is carried by the major depressive psychoses. Norris, for example, has recently shown that the crude death rates for men and women suffering from these conditions are respectively nine and six times the corresponding rates for persons of 16 years or more in the general population (6) .
When reasonably homogeneous groups can be constructed, the indices of response have to be defined. The clinical pharmacologist who employs quantitative methods to compare therapeutic substances may proceed by employing one of three methods (7) . These are the direct assay, in which measurement is made of the dose just necessary to produce an effect; the measured response of a dependent variable; and the assay by quantal, or all or none, responses which are not measured but recorded as being present or absent. With these techniques it is possible to study dose-response data according to the conditions of the experiment. Unfortunately the disturbances of function which accompany depressive states are insufficiently constant or sensitive to be employed in the way in which, for example, blood pressure can be used in the evaluation of hypotensive agents. This is true even of those physiological indices, like weight and certain autonomic responses, as well as those psychological concomitants like the altered psychomotor reactions, which are related intimately enough to some depressive illnesses to bear on prognosis. 50 years ago Eugen Bleuler commented of melancholia that "the affect is the index of the whole picture" (8) and most of the reported physical and psychological changes must still be regarded as epiphenomena. For this reason, in our present state of knowledge the outcome of depressive illnesses.and the response to treatment have still to be expressed usually in the holistic terms of clinical and social morbidity.
Ethical considerations demand that patients included in a clinical trial should not be deprived of the best available therapy. In many of the milder depressive illnesses this often comprises some non-specific form of pharmacological treatment or some form of psychotherapy. For a large proportion of the more severe illnesses, however, electrical shock therapy is available and cannot be lightly withheld for the experimental testing of a new compound. In all comparisons it is necessary to bear in mind that ECT, which despite much work and speculation remains an empirical procedure, carries a negligible mortality rate and that there are relatively few physical contraindications to its application when administered correctly. It is, nevertheless, a traumatic procedure which many patients and physicians find distasteful. Convulsive therapy has not been subjected to a formal therapeutic trial; most attempts at evaluation have been based on a comparison between the outcome of illnesses treated by ETC in hospital and the outcome of illnesses recorded by hospital controls in the pre-shock era (9) . These studies have shown that convulsive treatment reduces hospital mortality rates among patients with depressive illnesses (10) and that it also reduces the time which many of these patients spend in hospital (11) . Only 20 years ago mental hospitals could demonstrate the spectacle of whole wards containing" ... chronic melancholies, who had been in the hospital for two to over twenty years. They had lost the sharp edge of their depression but were anergic, almost inaccessible to stimulation and preoccupied with delusions of unworthiness, hopelessness and physical illness which gravely incapacitated them. Some spontaneously remitted, but there were always others to take their place" (12) . This corner of mental hospital life has mostly disappeared following the introduction of ECT. Several workers have since used the duration of stay in hospital as a useful indication of the severity of illness. They have shown that ECT can cut short and fragment many depressive reactions, particularly in the involutional period, but that it does not influence the disease-cycle of the individual patient who exhibits periodic attacks. Further, ECT is without detectable benefit in a proportion of cases from which, on clinical grounds, favourable response would be anticipated.
At the present time there is no pharmacological substance whose efficacy can match that of ECT in the treatment of major depressive illnesses. Many drugs have been tried and found wanting-amphetamine and its congeners, the barbiturates, endocrine preparations, dinitrile succinate, methylphenidate and iproniazid, to mention only a few -but it is now more necessary than ever to specify our expectations of any effective substances which may become available. Even though a drug were to be introduced on an empirical basis it would, of course, be necessary to ensure that it was without serious side effects and that it was oflow toxicity. This lesson has been very recently exemplified by iproniazid. If such a substance were no more effective than ECT it would probably find favour because of the advantages attached to its mode of administration, especially if this were by the oral route. In some instances these advantages might prove decisive even if drug therapy were in some measure inferior to ECT, for example in its speed of action. To establish its superiority over electrical treatment on clinical grounds a new drug could be responsible for one or a combination of the following effects: (a) it could reduce or abolish the mortality rate associated with depressive illnesses treated with ECT; (b) it could curtail the duration of the treated illness or mitigate the social disability still further; (c) it could prevent subsequent attacks; (d) it could prove to be efficacious in cases which had failed to respond to electrical treatment.
It is important to specify which of these features is being singled out in a comparative trial with ECT. By way of example there may be cited an experiment which we conducted with a drug reputed some years ago to be of value in the treatment of depressive states in the senium. These illnesses display several clinical and biological features in common and we attempted further to secure uniformity by choosing only patients admitted to our own geriatric unit. The patients, most of whom were in their seventh decade of life and suffering from affective illnesses uncomplicated by organic features, enjoyed in general a good prognosis, with an average period of stay in hospital of three months. It had always been the practice in this unit to assess patients for a period of time in hospital before the commencement of active treatment. Advantage was taken of this interval to introduce a double-blind procedure with drug and placebo over a period of about four weeks in which ECT was withheld. During this time blood pressure and weight were recorded, bi-weekly ratings of behaviour were made by doctors and nurses, side effects were noted and different dose schedules of drug were prescribed. Each case was reviewed at the end of this initial period, when the need for further treatment was considered and ECT was administered if it was considered necessary. The relevant results of this experiment are summarized in the table below. Total number of patients =72.
Though they have not been included in the table the dosages of drug administered were equally distributed among all groups. From these figures it is apparent, first, that most patients required ECT after the trial period on the drug; secondly, that a successful outcome was largely associated with the administration of ECT; and thirdly, that there was no significant difference between the outcome of drugtreated and placebo-treated groups whether electrical treatment was administered or not. It was therefore possible to conclude that in the treatment of depressive illnesses with these characteristics the drug was inferior to electrical treatment and no more efficacious than the placebo.
Relatively precise answers of this type are possible even with empirical remedies, and refinements of statistical method can sharpen such questions by, for example, indicating the degree of improvement which would be accepted as clinically worthwhile before the trial commences (13) . If, however, there is a rational basis for the introduction of pharmacological treatment another order of questions becomes possible within the framework of the therapeutic experiment. Thus in a recent study carried out by Pare and Stacey, iproniazid was administered to a group of depressed patients with the objectives of determining not merely whether the S124 CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL Vol. 4, 1959 drug was of benefit but also whether those patients who did respond could be differentiated clinically and biochemically (by estimations of urinary 5-hydroxyindoleacetic acid) from those who did not respond and, more specifically, whether among the positive respondents there was any evidence to suggest that their response was related to changes in the brain concentration of 5-hydroxytryptamine (5-HT) or of catecholamines (14) . Similarly the recent pharmacological studies which have shed light on the peripheral effects of amphetamine, particularly the liberation of norepinephrine and its 5-HT-like action, have suggested experiments to determine whether these effects are reproduced in the central nervous system of depressed patients responding to this drug. The theoretical importance. of such investigations is considerable since the information obtained in a therapeutic setting may be used to shed light on the mechanism of the disorder under study. This model may receive more attention with the accumulation of relevant information about the properties of substances in current use.
The drug treatment of the less severe depressive conditions is beset by problems of its own. These reactions include the large groups of loosely termed "neurotic," "reactive," or "exogenous" depression often admixed with the clinical manifestations of anxiety. Many of them run a chronic, fluctuating course. In such cases depression may represent a symptom as much as a syndrome and the indices of outcome which are available for the major depressive illnesses find limited application in their treatment. Only a minority of the patients require convulsive therapy. If they do attend hospital they are unlikely to require admission and it seems probable that many of them never come under psychiatric care. Recent studies of morbidity in general practice under the National Health Service in Great Britain have suggested that depressive illnesses rank high in the psychiatric case-load of the practitioner and that he treats the majority of patients himself (15) . It also seems probable from socio-medical inquiries that other patients suffering from these conditions do not come to medical attention at all but rely rather on the advice of the chemist or on self-medication. When the disability consists of no more than feelings of discontent, distress or discomfort, even social criteria like the workrecord may be too crude for purposes of assessment.
I t is notoriously difficult to apply the principles of the therapeutic trial to illnesses of this sort. Treatment can be evaluated by a group trial in favourable circumstances (16) but there are many practical and theroretical obstacles. The dropout rate is high and there is always uncertainty as to whether the patient is taking the drug or not. The diversity within diagnostic groups is considerable and impairs the possibility of generalization from the small numbers which are usually treated. Changes in the course of the condition may be linked more with interpersonal and social factors than with the patient's drug-treatment. The criteria of response in such trials depend moreover wholly or partly on clinical judgments by the observer and ratings of experience or drug-preference by the patient, criteria which are inevitably subjective. Finally, the wide individual variation of response to drugs (17) assumes such importance that it may be necessary to employ an experimental design which enables the information about individuals to be extracted.
An alternative method of tackling this problem is to concentrate directly on the universe of the individual patient and to study the intra-individual variation. This principle is familiar to physiologists and psychologists (18, 19) . Its application to therapeutics has been advocated by Hogben as a means of direct examination of the stimulus-response nexus. What he calls the self-controlled, self-recorded trial is designed to study therapeutic response in states of chronic, low-grade morbidity which are not regarded as reversible and where the end-points of therapy are defined by symptomatic relief rather than by cure (20) . The controlled investigation of subjective data in the form of symptoms is a central feature of the experimental S125 design. Symptoms are subdivided for the purpose into those which are usually associated with disturbances of behavior and so become open to observation, for example, anorexia, and those in which personal experiences predominate and render the subject's testimony the principal source of data, for example referred pain. Our experience suggests that the treatment of less severe chronic depressive states can be investigated in this way. The suitable subject is invited to complete pre-designed forms bearing on specified functions and experiences. The form can be filled in at regular intervals in normal working or domestic conditions. Internal checks are provided for subjective data, and the co-operation of an observer can be enlisted for the verification of functional disturbance. After a period of observation without treatment the effects of medication can be observed, the subject remaining in ignorance of the substance which he receives.
If the initial recordings are made in hospital the nursing staff will enable an estimate to be made of the reliability of the subject's observations. On discharge the subject's spouse can co-operate in the same way for regular recordings in the intervals between psychiatric assessments. Though the technique raises several problems in the selection of subjects, the recording of information and the mathematical treatment of summated indices, the data which it provides about natural fluctuations and the continuity of response make it a promising research tool in the study of these elusive conditions.
It now seems probable that we are soon to be presented with so many new anti-depressive compounds that the familiar clinical attitude of laissez-fairs empiricism will be increasingly difficult to sustain. The clinician is compelled to hold the balance between the scales of laboratory data on the one hand and stochastic theory on the other. Though his experience and judgment are essential it will be necessary for him to adopt a more experimental role in the future if he is to cooperate fully with the pharmacologist and the statistician, whose techniques he should understand if full weight is to be given to observations made in the clinical setting. More clinical research is indispensable to progress in the evaluation of drugs for the treatment of depression.
ReSUDle
Les epreuves cliniques, qu'elles soient diniques ou comparatives, comprennent tous les elements qu'il y a lieu d'observer pour I'appreciation d'un medicament nouveau. Des facteurs cliniques et ethiques determinent jusqu'a quel point ces elements peuvent hre pris en consideration. L'evaluation des substances medicamenteuses utilisees dans les etats depressifs doit tenir compte: a) de l'heterogeneite probable du materiel d'etude; b) du petit nombre d'indices mesurables permettant de juger de l'effet du traitement, specialernent dans les cas les moins graves. Toute therapeutique medicamenteuse des depressions doit pouvoir supporter la comparaison avec la therapeutique par choc electrique. Merrie s'il s'agit d'un remede empirique, son efficacite relative doit etre precisee et rapportee aux resultats bien connus de l' elecrrochoc. Si la medication est en treprise sur une base rationnelle, les resultats du traitement peuvent avoir une grande importance theorique, Dans le cas de la depression, affection relativement peu aigue, de nombreux obstacles se dressent sur le chemin d'une epreuve de groupe, et la composante subjective de la maladie acquiert une importance majeure pour I'evaluation de la therapeutique. Une experimentation clinique auto-controlee et auto-enregis tree peut etre tentee dans cet ordre d'idees,
Discussion
R. BRUCE SLOANE* I very much enjoyed Dr. Shepherd's paper and considered that he made a good case for controlled drug trials. Such studies seem to have undergone a kind of historical waxing and waning. Thus prior to the last decade or two, one seldom heard of them. Once they entered the scene, however, it became fashionable to decry results that were not "controlled" in this manner. But now the wheel has, as it were, turned full circle so that it is fashionable, even perhaps avant garde, to heap critical coals of fire upon such an approach. Thus, the double-blind study has been compared by Tuteur (1) to an illusion. He instances the so-called "objectivity" and says that judgment must be made without any possibility of bias, without any overcompensation for a possible bias, and without any possibility of the accusation of a possible bias. Naturally, he concludes with an impossibility: that such objectification is impossible, and not only impossible but unrealistic and perhaps also unrevealing. Other investigators believe that any such control is against their ethical dictates, others again that only by an intimate knowledge of the psychopathology of one patient can a true understanding of a drug's action be reached. At the other extreme lies the investigator who, mole-like, tunnels down his double-blind burrow, neglecting information, but secure in his belief in the safeguards of his methodology, as though everything will be revealed in the ultimate statistical wash.
Both attitudes seem to me to be based upon misconceptions of the difficulties involved in clinical trials. Whether these be of psychiatric or other patients, the problem lies in an attempt to separate out all the multitudinous factors involved in the therapeutic procedure. We are unable to exclude these variables and therefore must take cognizance of them. Thus, we have heard a great deal about the patient and the lack of knowledge of the aetiology of his illness, which in itself may take many shapes and forms. We have heard talk of the milieu in which the treatment occurs, the so-called psycho-social factors. However, we have heard little of the therapist who is administering the treatment. If we take into account that there are widely differing therapists, we also have to take into account that they may need to use the same drug and therefore wish to know more about its specific pharmacological action. Thus, by temperament, certain investigators seem more able to stand aloof and observe their patients, perhaps from the end of the ward, their critics will say, in contrast to others who plunge in with great enthusiasm, using their drugs almost as extensions of their own body image.
It is perhaps easier to see the symbolic value of the drug to the patient than to the doctor. However, it becomes impossible to escape the conclusion that the latter frequently, if not invariably, uses a remedy in proportion to his belief in its efficacy. His very beliefs may colour his observations, as perhaps they did in the case of our patients who described Tofranil as varying in colour from a beautiful salmon pink to a dirty brown. I fear that I am not one of those who believe that man is objective; rather do I believe that he is intensely subjective, if not even at times frankly procrustean. He sees what he wants to see and ignores what he doesn't want to see. There is no reason to deplore such subjectivity, no reason to contrast subjectivity with objectivity to the detriment of the former, but merely to underline its presence for the purposes of study. Whether such study is always necessary I am not sure -perhaps one should merely be satisfied with one's patients getting better.
From the clinician's point of view, the most widely voiced and, in Bradford Hill's view, "the most foolish criticism of the statistical approach in medicine, is that human beings are too variable to allow 'Professor and Head of Department of Psychiatry, Queen's University, Kingston, Ontario. S127 of the contrast inherent in a controlled trial of a remedy" (2) . Thus, he continues that "if each patient is unique there can be nothing for the statistician to count, but, if this is true, it has always seemed to me that the bottom falls out of the clinical approach as well as the statistical. If each patient is unique, how can the basis of treatment be found in the past observations of other patients? In fact, of course, physicians do not act like this; they base their methods of choice upon what they have seen happen before, whether it be in only two or three cases or in a score." Nevertheless, in such a comparison we immediately encounter subjective bias.
To help us in this maze of variability we are forever seeking to establish parameters. In this context, I would wish to speak of only one of the parameters that have been mentioned, not only by Dr. Shepherd, but throughout this meeting, namely the constancy of response of the depressed patient to electroconvulsive therapy. If this becomes our yardstick of measurement against which we assess other treatments, perhaps we should re-examine our criterion. I am well aware that when I suggest that ECT in major depressive iIIness* may not be the panacea sometimes suggested, I become an iconoclast and risk all the feeling that those who criticize icons arouse. Dr. Freyhan has drawn attention to the conflicting evidence in the literature suggesting that such illness may perhaps be better treated by other methods than shock treatment. I have little reason to doubt Dr. Cook's memories of the wards at Bexley when he first went there. However, I wonder whether memory is always a good substitute for controlled and recorded observation and whether the changes that have occurred may only in part be due to the introduction of physical treatment. Karagulla, in a controversial paper reviewing the admissions to the Royal Edinburgh Hospital for Mental and Nervous Disorders during the years 1900 to 1948, carefully studied 923 patients in 1611 hospital admissions (3) . Her most important finding was perhaps that 80-90% of depressed patients recovered or improved and that the proportion who did not improve remained constant between the era when ECT was available and the era when it was not. 61% of these patients had only one admission to hospital for a depressive illness, and a relatively large number of patients required only 6 weeks' stay in hospital. These findings emphasized, in her words, "the high expectation of recovery in depressive states and this in turn underlined the necessity for the application of stringent criteria in the evaluation of any form of therapy which claims to accelerate this process of natural recovery." Her other conclusions, namely that the use of ECT did not shorten the duration of hospital stay, that it did not increase the percentage discharged from hospital, that those who were classified as recovered with ECT showed a somewhat higher tendency toward readmission than those who recovered without ECT, and that the suicide rate was slightly higher in those treated with ECT than in those not treated with ECT, have all been variously criticised, most notably by Slater (4). However, even if these are discounted, her paper still underlines the good prognosis in most hospitalized depressions and the failure of ECT to influence the outcome of those with a bad prognosis. Thus, I wonder how many patients, even with severe illness, would recover, and perhaps in not much longer a time than with ECT, if merely rested in the protective environment of a hospital. I consider that the reason they are not treated in this way lies in the enormous importunity presented by the patients' symptoms and the demands of the relatives for the doctor to produce quick relief. In this way, I would echo Dr, Lehmann's words that the psychiatric tolerance to depressive symptoms in patients has been so much reduced during the last IS years that many psychiatrists may find it difficult to wait 2-4 weeks before seeing a definite lifting of depression in their patients. Nevertheless, the efficacy of a method of treatment of a disease may be better judged by the long-term results over perhaps a period of 5-10 years than by the immediate improvement, gratifying though it be to the attendant physician. Perhaps harm may be done by attempting an undue shortening of the period of sickness occasioned by depressive illness. Without knowledge of relapse and readmission rates, short hospital stays are meaningless.
Here, however, I consider that Tofrjinil has a most important role to play. By its sedative action it seems to reduce both the suffering of the patient and perhaps the guilt experienced by psychiatrist and nurse in allowing the patient to bear his illness during the longer period of time required by "spontaneous" remission. In this way, perhaps, the drug can be regarded as a solvent of superego not only in the patient but also in his attendants.
Thus, in conclusion, I would say that if Tofranil played no greater part, and I personally feel sure that it will, than in helping us to re-examine the natural history of major depressive illness, its advent will have been well worth while. *Defined empirically as depressive illness in which the majority of psychiatrists would nowadays adjudge the patient suitable for ECT.
Vol. 4, 1959 study; (3) A clear picture of the natural history of the variables under study; (4) Knowledge about the relationship between the population studied and the general population in which the variable as a whole exists. This speaker felt that most papers presented to date had been really preliminary statements. The efficacy of the therapist's clinical judgment in assessing a patient's progress and thereby providing a control was stressed by several discussants.
Reference was made to the time factor; it was noted that in the New York area electroshock is more commonly used where the length of stay of the patient has more direct economic repercussions upon each individual. It was stressed that in discussing one new approach to the treatment of one disease, there is no implication that one should thereby throw out all other treatments which have previously been proved efficacious. The fact that an increasing number of approaches is available is felt to be an index of progress in psychiatry.
